These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10429510

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
    Nock BA, Nikolopoulou A, Reubi JC, Maes V, Conrath P, Tourwé D, Maina T.
    J Med Chem; 2006 Jul 27; 49(15):4767-76. PubMed ID: 16854083
    [Abstract] [Full Text] [Related]

  • 3. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties.
    Maes V, Garcia-Garayoa E, Bläuenstein P, Tourwé D.
    J Med Chem; 2006 Mar 09; 49(5):1833-6. PubMed ID: 16509599
    [Abstract] [Full Text] [Related]

  • 4. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.
    Zhang K, An R, Gao Z, Zhang Y, Aruva MR.
    Nucl Med Biol; 2006 May 09; 33(4):505-12. PubMed ID: 16720242
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.
    García-Garayoa E, Allemann-Tannahill L, Bläuenstein P, Willmann M, Carrel-Rémy N, Tourwé D, Iterbeke K, Conrath P, Schubiger PA.
    Nucl Med Biol; 2001 Jan 09; 28(1):75-84. PubMed ID: 11182567
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.
    García-Garayoa E, Bläuenstein P, Blanc A, Maes V, Tourwé D, Schubiger PA.
    Eur J Nucl Med Mol Imaging; 2009 Jan 09; 36(1):37-47. PubMed ID: 18690434
    [Abstract] [Full Text] [Related]

  • 8. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
    Alshoukr F, Rosant C, Maes V, Abdelhak J, Raguin O, Burg S, Sarda L, Barbet J, Tourwé D, Pelaprat D, Gruaz-Guyon A.
    Bioconjug Chem; 2009 Aug 19; 20(8):1602-10. PubMed ID: 19610615
    [Abstract] [Full Text] [Related]

  • 9. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
    García-Garayoa E, Bläuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, Tourwé D, Schubiger PA.
    J Nucl Med; 2002 Mar 19; 43(3):374-83. PubMed ID: 11884498
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
    García-Garayoa E, Maes V, Bläuenstein P, Blanc A, Hohn A, Tourwé D, Schubiger PA.
    Nucl Med Biol; 2006 May 19; 33(4):495-503. PubMed ID: 16720241
    [Abstract] [Full Text] [Related]

  • 12. Neurotensin(8-13) analogue: radiolabeling and biological evaluation using different chelators.
    Teodoro R, Faintuch BL, Núñez EG, Queiróz RG.
    Nucl Med Biol; 2011 Jan 19; 38(1):113-20. PubMed ID: 21220134
    [Abstract] [Full Text] [Related]

  • 13. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
    Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL.
    J Med Chem; 2003 Jul 17; 46(15):3403-11. PubMed ID: 12852770
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs.
    Bergmann R, Scheunemann M, Heichert C, Mäding P, Wittrisch H, Kretzschmar M, Rodig H, Tourwé D, Iterbeke K, Chavatte K, Zips D, Reubi JC, Johannsen B.
    Nucl Med Biol; 2002 Jan 17; 29(1):61-72. PubMed ID: 11786277
    [Abstract] [Full Text] [Related]

  • 15. Improving the tumor uptake of 99mTc-labeled neuropeptides using stabilized peptide analogues.
    Bläuenstein P, Garayoa EG, Rüegg D, Blanc A, Tourwé D, Beck-Sickinger A, Schubiger PA.
    Cancer Biother Radiopharm; 2004 Apr 17; 19(2):181-8. PubMed ID: 15186598
    [Abstract] [Full Text] [Related]

  • 16. [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.
    Gabriel M, Decristoforo C, Wöll E, Eisterer W, Nock B, Maina T, Moncayo R, Virgolini I.
    Cancer Biother Radiopharm; 2011 Oct 17; 26(5):557-63. PubMed ID: 21883013
    [Abstract] [Full Text] [Related]

  • 17. Radiolabeled ligands specific for the G protein-coupled state of neurotensin receptors.
    Gaudriault G, Zsürger N, Vincent JP.
    J Neurochem; 1996 Dec 17; 67(6):2590-8. PubMed ID: 8931494
    [Abstract] [Full Text] [Related]

  • 18. A novel tetrabranched neurotensin(8-13) cyclam derivative: synthesis, 64Cu-labeling and biological evaluation.
    Röhrich A, Bergmann R, Kretzschmann A, Noll S, Steinbach J, Pietzsch J, Stephan H.
    J Inorg Biochem; 2011 Jun 17; 105(6):821-32. PubMed ID: 21497581
    [Abstract] [Full Text] [Related]

  • 19. '2+1' Tricarbonyltechnetium(I) and -rhenium(I) mixed-ligand complexes with N-methylpyridine-2-carboxyamide and isocyanide or imidazole ligands-potential precursors of radiopharmaceuticals.
    Fuks L, Gniazdowska E, Kozminski P, Lyczko M, Mieczkowski J, Narbutt J.
    Appl Radiat Isot; 2010 Jan 17; 68(1):90-5. PubMed ID: 19766012
    [Abstract] [Full Text] [Related]

  • 20. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.
    Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, Reubi JC, Bläuenstein P, Tourwé D, García Garayoa E, Bischof Delaloye A.
    J Nucl Med; 2003 Oct 17; 44(10):1649-54. PubMed ID: 14530481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.